NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...
Hosted on MSN
MindMed outlines 2026 Phase III trial readouts and advances MM120 commercialization with new CFO
Earnings Call Insights: Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 CEO Robert Barrow highlighted that MindMed remains "on track with enrollment with our three pivotal Phase III trials for our lead ...
-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- --Anticipated topline data ...
Verywell Health on MSN
Cymbalta vs. Lexapro for depression: Which is better?
Cymbalta and Lexapro are both used to treat depression and anxiety disorders, but they are different drug classes. Cymbalta ...
NEW YORK, June 21 (Praxis Press) Generalized anxiety disorder (GAD) is associated with debilitating psychic and somatic symptoms. Previous studies have found that Venlafaxine extended-release (XR) ...
- Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 ...
Findings highlight the link between anxiety severity and SI, underscoring the need for routine screening NEW YORK--(BUSINESS WIRE)-- Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the ...
--Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- --Data from the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results